These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15063356)

  • 1. Matrix metalloproteinases, oxidative stress and the acute response to acute myocardial ischaemia and reperfusion.
    Wainwright CL
    Curr Opin Pharmacol; 2004 Apr; 4(2):132-8. PubMed ID: 15063356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction.
    Cleutjens JP; Creemers EE
    J Card Fail; 2002 Dec; 8(6 Suppl):S344-8. PubMed ID: 12555143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction.
    Tziakas DN; Chalikias GK; Hatzinikolaou EI; Stakos DA; Tentes IK; Kortsaris A; Hatseras DI; Kaski JC
    Am J Cardiol; 2005 Jul; 96(1):31-4. PubMed ID: 15979428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart.
    Lalu MM; Pasini E; Schulze CJ; Ferrari-Vivaldi M; Ferrari-Vivaldi G; Bachetti T; Schulz R
    Eur Heart J; 2005 Jan; 26(1):27-35. PubMed ID: 15615796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture.
    Newby AC
    Physiol Rev; 2005 Jan; 85(1):1-31. PubMed ID: 15618476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Definition and pathophysiology of acute coronary syndrome].
    Fujimoto H; Yamaguchi T
    Nihon Rinsho; 2006 Apr; 64(4):611-6. PubMed ID: 16613176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases in critical limb ischemia.
    Hobeika MJ; Edlin RS; Muhs BE; Sadek M; Gagne PJ
    J Surg Res; 2008 Sep; 149(1):148-54. PubMed ID: 18155249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload.
    Janicki JS; Brower GL; Gardner JD; Forman MF; Stewart JA; Murray DB; Chancey AL
    Cardiovasc Res; 2006 Feb; 69(3):657-65. PubMed ID: 16376324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases and their inhibitors in non-neoplastic otorhinolaryngological disease.
    De S; Fenton JE; Jones AS
    J Laryngol Otol; 2005 Jun; 119(6):436-42. PubMed ID: 15992468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.
    Spinale FG
    Physiol Rev; 2007 Oct; 87(4):1285-342. PubMed ID: 17928585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of matrix metalloproteinases in the oral environment.
    Hannas AR; Pereira JC; Granjeiro JM; Tjäderhane L
    Acta Odontol Scand; 2007 Feb; 65(1):1-13. PubMed ID: 17354089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization.
    Cevik C; Otahbachi M; Nugent K; Warangkana C; Meyerrose G
    J Cardiovasc Med (Hagerstown); 2008 Dec; 9(12):1274-8. PubMed ID: 19001938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
    Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.
    Galis ZS; Khatri JJ
    Circ Res; 2002 Feb; 90(3):251-62. PubMed ID: 11861412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
    Janssens S; Lijnen HR
    Cardiovasc Res; 2006 Feb; 69(3):585-94. PubMed ID: 16426591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling.
    Apple KA; Yarbrough WM; Mukherjee R; Deschamps AM; Escobar PG; Mingoia JT; Sample JA; Hendrick JW; Dowdy KB; McLean JE; Stroud RE; O'Neill TP; Spinale FG
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):228-35. PubMed ID: 16495760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.
    Tziakas DN; Chalikias GK; Parissis JT; Hatzinikolaou EI; Papadopoulos ED; Tripsiannis GA; Papadopoulou EG; Tentes IK; Karas SM; Chatseras DI
    Int J Cardiol; 2004 Apr; 94(2-3):269-77. PubMed ID: 15093992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction.
    Fang L; Gao XM; Moore XL; Kiriazis H; Su Y; Ming Z; Lim YL; Dart AM; Du XJ
    J Mol Cell Cardiol; 2007 Nov; 43(5):535-44. PubMed ID: 17689559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating matrix metalloproteinase 3 due to myocardial ischemia.
    Siminelakis S; Kotsanti A; Kolaitis N; Niokou D; Vlachou I; Dimakopoulos G; Papadopoulou C
    Heart Surg Forum; 2009 Aug; 12(4):E230-4. PubMed ID: 19683995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.